Adding to recent setbacks in the development of Leqembi (lecanemab), US firm Biogen (Nasdaq: BIIB) has revealed a filing for a subcutaneous formulation will be delayed.
On the positive side, the company has submitted to broaden the label for the ground-breaking Alzheimer’s therapy, to include a maintenance dosing regimen.
If successful, the update would enable a reduction in the number of required infusions, with patients able to move on to a monthly schedule.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze